

EudraCT number: 2019-000406-30

Sponsor Company: Allergan

Study Title: Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis

Please note the following: Although a EudraCT number was assigned for this trial, no subjects were enrolled in the EU and the compound does not fall under a marketing authorization in the EU. Therefore, Allergan will not be submitting study results.